Abstract
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
| Original language | English |
|---|---|
| Pages (from-to) | 171-182 |
| Number of pages | 12 |
| Journal | Exploration of Targeted Anti-tumor Therapy |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Cancer Research
- Oncology
Keywords
- BRCA1 and 2
- DNA repair
- PARP-inhibitors
- homologous recombination deficiency
- ovarian cancer
Fingerprint
Dive into the research topics of 'Integration of PARP-inhibitors in ovarian cancer therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver